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ABSTRACT 
 
Objectives 
Colorectal polyp cancers present clinicians with a treatment dilemma. Decisions of whether to offer 
segmental resection or endoscopic surveillance are often taken without reference to good quality 
evidence. The aim of this study was to develop a treatment algorithm for patients with screen-
detected polyp cancers. 
 
Design 
This national cohort study included all patients with a polyp cancer identified through the Scottish 
Bowel Screening Programme (SBoSP) between 2000 and 2012. Multivariate regression analysis 
was used to assess the impact of clinical, endoscopic and pathological variables on the rate of 
adverse events (residual tumour in patients undergoing segmental resection or cancer-related death 
or disease recurrence in any patient). These data were used to develop a clinically relevant 
treatment algorithm. 
 
Results 
485 patients with polyp cancers were included. 186/485 (38%) underwent segmental resection and 
residual tumour was identified in 41/186 (22%). The only factor associated with an increased risk of 
residual tumour in the bowel wall was incomplete excision of the original polyp (OR 5.61, p=0.001) 
while only lymphovascular invasion was associated with an increased risk of lymph node 
metastases (OR 5.95, p=0.002). When patients undergoing segmental resection or endoscopic 
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surveillance were considered together, the risk of adverse events was significantly higher in patients 
with incomplete excision (OR 10.23, p<0.001) or lymphovascular invasion (OR 2.65, p=0.023). 
 
Conclusions 
A policy of surveillance is adequate for the majority of patients with screen-detected colorectal 
polyp cancers. Consideration of segmental resection should be reserved for those with incomplete 
excision or evidence of lymphovascular invasion. 
 
Abstract word count = 249  
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SUMMARY ‘BOX’ 
What is already known about this subject? 
 Population bowel screening programmes lead to large numbers of colonoscopies being 
carried out in asymptomatic patients. 
 As a result, the inadvertent discovery of cancer within an excised colorectal polyp has 
become increasingly common.  
 The dilemma facing clinicians is whether to offer patients segmental resection or endoscopic 
surveillance. 
 Current guidelines for polyp cancer management are based on poor quality evidence. 
 
What are the new findings? 
 The long-term survival of patients with polyp cancers is excellent, regardless of 
management strategy. 
 Over three quarters of patients who undergo segmental resection have no evidence of 
residual tumour when their specimens are examined. 
 Incomplete excision and evidence of lymphovascular invasion are the only independent 
predictors of residual tumour, disease recurrence and cancer-related death. 
 Treatment decisions must be tailored to avoid unnecessary surgery. 
 
 
How might it impact on clinical practice in the foreseeable future? 
 A new treatment algorithm for colorectal polyp cancers is proposed.  
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INTRODUCTION 
 
Colorectal cancer is the third most common cancer in the Western world, responsible for over 
16,000 deaths annually in the United Kingdom alone 1.  There is now robust evidence that 
population screening can reduce cancer-related mortality by detecting and treating disease at an 
early stage2 3.  Indeed, an analysis of the first million tests carried out in the English National Bowel 
Cancer Screening Programme reported that 10% of the cancers detected were evident only as a 
focus of malignancy within an excised colorectal polyp 4. The diagnosis of these early malignant 
lesions, termed ‘polyp cancers’, is likely to become increasingly common as population screening 
programmes become established around the world 5.  
 
The management of polyp cancers is difficult because of the possibility that residual tumour cells 
remain within the bowel wall or loco-regional lymph nodes following endoscopic polypectomy. 
The endoscopist is usually unaware that the polyp being excised contains a focus of cancer and the 
subsequent histological diagnosis is therefore unexpected. The dilemma then is whether such 
patients can be managed with surveillance alone or whether operative intervention is required. A 
segmental resection serves to clear the patient of the risk of residual tumour but carries inherent 
morbidity and mortality. Given that a proportion of patients undergoing resection have no evidence 
of residual disease when their specimens are examined 6-8, it could be argued that such patients are 
being exposed to unnecessary risk.  
 
To assist decision-making, several guidelines for the management of colorectal polyp cancers exist, 
including those published by the Scottish Intercollegiate Guidelines Network (SIGN) 9 and the 
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National Institute for Health and Care Excellence (NICE) 10. However, the underlying evidence 
base is poor and the resultant recommendations are necessarily pragmatic. Much of the literature to 
date has focused on whether individual pathological features can predict the risk of residual disease 
in patients undergoing surgery and knowledge regarding the long term outcomes of those surveyed 
endoscopically is lacking 7 11 12.  
 
It is clear from a recent position statement by the Association of Coloproctologists of Great Britain 
and Ireland (ACPGBI) that the management of polyp cancers currently presents the colorectal 
multidisciplinary team (MDT) with a considerable challenge 13. To address this topic, the present 
study sought to establish the incidence, management strategies and outcomes for all polyp cancers 
diagnosed through population screening in Scotland. The primary aim was to develop an evidence-
based treatment algorithm for patients with screen-detected colorectal polyp cancers. 
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PATIENTS & METHODS 
 
The Scottish Bowel Screening Programme 
Population screening in Scotland was piloted from April 2000 before a phased national roll out was 
commenced in June 2007. By December 2009 all NHS Health Boards in the country were 
participating. The programme dictates that all men and women aged 50 to 74 are invited to 
complete a guaiac-based faecal occult blood test (gFOBt) every 2 years. Those with positive test 
results are referred to their local hospital for assessment and investigation with colonoscopy 14.  
 
Patient involvement 
The study was conducted by the Scottish Surgical Research Group (SSRG), a trainee-led research 
collaborative, in conjunction with the Scottish Bowel Screening Programme (SBoSP). Outcome 
measures were chosen for their ability to influence how patients could make more informed 
treatment decisions. The study design was endorsed by professional and lay members of the SBoSP 
steering committee. 
 
Inclusion and exclusion criteria 
For the purposes of this study, a polyp cancer was defined as a colorectal polyp where primary 
excision was carried out endoscopically and where there was subsequent histological evidence of 
neoplastic cells having invaded through the muscularis mucosae into the submucosa. Cases were 
identified by interrogating the SBoSP database, a prospectively maintained database containing 
information on all patients who have participated in screening. All polyp cancers diagnosed since 
the start of the pilot programme on 01 April 2000 until 31 December 2012 were included.  To 
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ensure reliability of data, the original endoscopy and histopathology reports of each potential case 
were reviewed on an individual basis and the following exclusion criteria applied; (1) specimens 
that were a biopsy of an invasive carcinoma, (2) polyps with high grade dysplasia only, (3) cases 
with a synchronous invasive cancer elsewhere in the colorectum, (4) cases with insufficient data to 
confirm the diagnosis. Finally, for included cases, medical records were retrieved from local health 
boards and clinical, endoscopic, radiological and pathological data recorded using a standardised 
proforma.  
 
Primary outcome 
The primary outcome was the number of adverse events. An adverse event was defined as any of 
the following; (1) evidence of tumour in the resected specimen of patients undergoing segmental 
resection, (2) cancer-related death in any patient, regardless of management strategy, (3) local or 
systemic disease recurrence in any patient, regardless of management strategy. Information on date 
and cause of death was obtained from the national cancer registration system and cross-checked 
with that received by the Registrar General (Scotland). Death records were considered complete up 
to 31 December 2012, which served as the censor date.  Overall, cancer-specific and recurrence-free 
survival was measured from the date of the screening colonoscopy until the date of death or 
confirmed disease recurrence.  
 
Clinico-pathological variables  
Endoscopic variables recorded included polyp location, polyp morphology and polypectomy 
technique used during the initial colonoscopy. Pathological variables were recorded from 
contemporary laboratory reports and included details of whether the specimen had been reviewed 
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centrally by an independent panel of screening programme pathologists. Variables recorded 
included polyp size, differentiation and the presence of lymphatic and/or venous invasion (termed 
lymphovascular invasion). If the invasive margin could be reliably assessed pathologically and was 
free of tumour (regardless of distance), it was regarded as ‘completely excised’.   If the margin 
could not be assessed or if there was evidence of tumour extending to the diathermy edge, it was 
regarded as ‘incompletely excised’. Where documented, the margin clearance in millimetres (mm) 
was also recorded. Pathological assessment of the depth of submucosal (sm) invasion according to 
the Haggitt 15 and Kikuchi 16 systems were included where documented. The Haggit levels of 
invasion in pedunculated polyps are defined as follows. Level 1: carcinoma invading into the 
submucosa but limited to the head of the polyp; Level 2: carcinoma invading to the level of the 
neck; Level 3: carcinoma invading any part of the stalk; Level 4: carcinoma invading into the 
submucosa below the level of the stalk but above the muscularis propria. The Kikuchi classification 
relates to sessile polyps and is defined as follows. An sm1 tumour invades into the upper third of 
the submucosa, an sm2 tumour invades into the middle third and an sm3 tumour invades into the 
lower third of the submucosa. 
 
Demographic data included age, sex, body mass index (BMI) and comorbidity profile. The latter 
was assessed using the Charlson Comorbidity Index, a validated method for quantifying the burden 
of comorbidity17. Surgical outcomes in patients undergoing segmental resection (right 
hemicolectomy, left hemicolectomy, sigmoid colectomy, anterior resection, subtotal colectomy) or 
transanal excision microsurgery (TEMS) included length of stay and 30 day rates of mortality and 
morbidity. Post-operative complications were classified according to Clavien-Dindo criteria and 
graded as ‘minor’ (grade I/II) or ‘major’ (grade III/IV) 18.  
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.   
Statistical analysis 
Grouping of variables was carried out using previously published or clinically relevant thresholds. 
Categorical variables were compared using Chi-square tests and binary logistic regression with 
calculation of odds ratios (OR) and 95% confidence intervals (CI). Continuous variables were 
compared using appropriate parametric and non-parametric tests. Multivariate analyses of 
associations with adverse events were carried out using a binary logistic regression model. P values 
<0.05 were considered statistically significant. Statistical analyses were performed using SPSS 
software (Version 19.0, IBM SPSS Inc., Chicago, IL). 
 
Ethical review 
Ethical approval was sought and obtained from the NHS Scotland Caldicott Guardian who 
confirmed that the study fulfilled the criteria of a clinical audit, obviating the requirement for 
further ethical committee approval. 
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RESULTS 
 
The total number of invitations sent, screening colonoscopies carried out and number of cancers 
diagnosed through national screening in Scotland are shown in Figure 1. Since the programme 
began there have been 3202 bowel cancers identified. Interrogation of the SBoSP database 
originally identified 772 cases as possible polyp cancers. After examining medical records, 287 
cases were excluded (143 were a biopsy only, 90 had no evidence of invasive malignancy, 10 had 
synchronous cancers, 35 had insufficient data and 9 were excluded for other reasons e.g. polyps not 
detected through screening) and 485 cases were included. Polyp cancers therefore comprised 15% 
(485/3202) of all screen-detected cancers with an annual incidence of 11 per 100,000 patients 
screened. 
 
The summary characteristics of the 485 included cases are shown in Table 1. The vast majority of 
polyp cancers were located in the left colon (75%) or rectum (18%) with the morphology 
pedunculated in 58% and sessile in 31%. According to the original colonoscopy report, 71% of 
polyps were removed intact and 21% were excised piecemeal. The focus of tumour was considered 
incompletely excised in 39% (tumour extended to the diathermy edge in 27%; margin not 
assessable in 12%). The polyp specimen underwent central pathological review in 110/485 (23%) 
of cases (Table 1).  
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Table 1. Summary characteristics of the included patients. 
 
Variable  485 (%) 
Age  ≤ 70 years 351 (72) 
 > 70 years 134 (28) 
Sex Female 162 (33) 
 Male 323 (67) 
BMI Normal (<25 kg/m2) 74 (15) 
 Overweight (25-30  kg/m2) 147 (30) 
 Obese (≥30 kg/m2) 88 (18) 
 missing 176 (36) 
Charlson Comorbidity Index 0-2 (fit) 251 (52) 
 ≥3 (unfit) 186 (38) 
 missing 48 (10) 
Polyp  location Right colon 28 (6) 
 Left colon 363 (75) 
 Rectum 88 (18) 
 Not recorded 6 (1) 
Polyp size  < 10mm 101 (21) 
 ≥ 10mm 326 (67) 
 Not recorded 58 (12) 
Polyp  morphology Pedunculated 283 (58) 
 Sessile    149 (31) 
 Not recorded 53 (11) 
Polypectomy  technique ¥ Intact 345 (71) 
 Piecemeal 103 (21) 
 Not recorded 37 (8) 
Polyp differentiation Well/moderate 337 (70) 
 Poor 45 (9) 
 Not recorded 103 (21) 
Lymphovascular invasion Absent/not recorded 400 (82) 
 Present 85 (18) 
Completeness of  excision Complete † 296 (61) 
 Incomplete  (tumour to diathermy edge) 133 (27) 
 Incomplete (not assessable) 56 (12) 
Margin clearance >1mm 178 (37) 
 ≤1mm 251 (52) 
 Not assessable 56 (12) 
Kikuchi level Sm1 10 (2) 
 Sm 2 18 (4) 
 Sm 3 7 (1) 
 Not recorded 450 (93) 
Haggit level Level 1/2 47 (10) 
 Level 3/4 30 (6) 
 Not recorded 408 (84) 
* Chi-square test 
¥ According to screening colonoscopy report 
†Complete excision is defined as a pathologically assessable margin that is free of tumour  
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The strategies employed in the management of the patients with polyp cancers are summarised in 
Figure 2. There was documentation that the initial treatment decision was taken by a colorectal 
MDT in the majority of cases (74%).  Over three quarters of patients (76%) were staged with a 
computed tomography (CT) scan (data not shown). Of note, there was a change from the 
intended treatment plan in a number of patients. The reasons for this were often not apparent 
from case note review but, where documented, included patient preference (n=10), fitness for 
surgery (n=2) and failed attempts at endoscopic re-resection (n=5). The final management 
strategy was a segmental resection in 186/485 (38%) and endoscopic surveillance in 299/485 
(62%). Of the patients who underwent segmental resection, 186/485 (22%) had evidence of 
tumour in their resected specimens and 299/485 (78%) did not (Figure 2).  
 
The operations performed, surgical outcomes and final pathology of the 186 patients who 
underwent segmental resection are shown in Table 2. Pathological examination of the resected 
bowel revealed evidence of residual tumour in 41/186 (22%) specimens. There was evidence of 
lymph node metastases in a total of 15/186 (8%) (Table 2). 
 
Factors associated with the presence of residual disease in the bowel wall or lymph nodes in 
patients undergoing segmental resection are shown in Table 3. Following resection, the only 
factor associated with an increased risk of residual disease in the bowel wall was pathological 
evidence of incomplete excision (OR 5.61, p=0.001). The only factor that significantly increased 
the risk of lymph node metastases was evidence of lymphovascular invasion in the original polyp 
(OR 5.95, p=0.002) (Table 3). 
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Table 2. Operations, surgical outcomes and final pathology of the 186 patients who underwent 
segmental resection of a screen-detected polyp cancer. 
 
 
Type of operation  186  (%) 
Right hemicolectomy  15 (8) 
Left hemicolectomy  18 (10) 
Sigmoid colectomy  42 (23) 
Anterior resection  90 (48) 
Subtotal colectomy  5 (3) 
Abdominoperineal resection  3 (2) 
TEMS  7 (4) 
Unknown  6 (3) 
Operative Outcomes   
Length of stay (days)     median (range)  7 (1-152) 
Mortality*  0 (0) 
Morbidity*  60 (32) 
Major morbidity†  21 (11) 
Anastomotic leak  7 (3.8) 
Final Pathology   
Residual tumour  41 (22) 
Residual tumour location Luminal only 26 (14) 
 Nodal only 3 (2) 
 Luminal and nodal 12 (6) 
T stage Ω 1 168 (90) 
 2 11 (6) 
 3 5 (3) 
 4 2 (1) 
N stage 0 171 (92) 
 1 12 (6) 
 2 3 (2) 
Differentiation Well 4 (10) 
 Moderate 22 (53) 
 Poor 5 (12) 
 Not recorded 10 (24) 
EMVI No 35 (85) 
 Yes 6 (15) 
Number of nodes examined  Median (range) 9 (1-51) 
* 30 day rate            † Clavien-Dindo grade 3 or 4 
Ω Patients with no evidence of residual disease in the resected bowel were designated as pT1 for staging purposes 
EMVI; Extra-mural venous invasion           
TEMS; transanal excision microsurgery 
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Long term outcomes are summarised in Figure 2. The median length of follow up was 50 months 
(minimum 16 months). Death records were complete up to 31 December 2014. The five-year 
overall, cancer-specific and recurrence-free survival of the cohort was 90%, 98% and 92% 
respectively. There was no difference in overall (p=0.78, log rank test) or cancer-specific 
(p=0.07, log rank test) survival between patients managed by segmental resection or endoscopic 
surveillance. Patients managed by segmental resection had a higher rate of systemic recurrence 
compared to those managed with endoscopic surveillance (6.5% versus 2.7%, X2 value = 4.13, df 
= 1, p=0.042) although the rates of local recurrence were similar (2.2% versus 1.3%, X2 value = 
0.467, df = 1, p=0.49). Overall, the recurrence-free survival was significantly shorter in patients 
managed by segmental resection (median time to recurrence 45 months versus 53 months, 
p=0.008, log rank test) (data not shown).   
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Table 3. Factors associated with the presence of residual disease in the bowel wall or lymph nodes of the 186 patients who underwent 
segmental resection of screen-detected polyp cancers.  
 
Variable  
Residual disease in bowel wall Residual disease in lymph nodes 
N (%)  O.R. 95% C.I. p value* N (%)  O.R. 95% C.I. p value* 
Age ≤ 70 years 31 (24)    14 (10)    
 > 70 years 7 (17) 0.76 0.31-1.87 0.55 1 (2) 0.23 0.03-1.83 0.17 
Sex Female 11 (18)    6 (10)    
 Male 27 (21) 1.22 0.56-2.65 0.63 9 (7) 0.69 0.24-2.04 0.51 
BMI < 25  kg/m2 4 (14)    1 (3)    
 > 25 kg/m2 16 (19) 1.52 0.46-4.97 0.49 7 (9) 2.61 0.31-22.21 0.38 
Charlson Comorbidity 
Index 
0-2 (fit) 21 (20)    5 (6)    
 ≥3 (unfit) 17 (24) 1.28 0.62-2.65 0.50 8 (11) 2.13 0.71-6.43 0.18 
Polyp location Colon 31 (20)    13 (9)    
 Rectum 7 (21) 1.01 0.40-2.54 0.98 2 (6) 0.67 0.14-3.11 0.61 
Polyp size < 10mm   8 (25)    2 (6)    
 ≥ 10mm 27 (21) 0.79 0.32-1.95 0.60 11 (9) 1.39 0.29-6.59 0.68 
Polyp morphology Pedunculated 17 (18)    8 (8)    
 Sessile 16 (24) 1.47 0.68-3.17 0.33 7 (11) 1.29 0.44-3.75 0.64 
Polyp differentiation Well/mod 24 (19)    10 (8)    
 Poor 2 (9) 0.41 0.09-1.86 0.25 3 (13) 1.76 0.44-6.94 0.42 
Lymphovascular invasion 
Absent/not 
recorded 
31 (23)    5 (4)    
 Present 7 (13) 0.50 0.21-1.22 0.13 10 (19) 5.95 1.93-18.39 0.002 
Completeness of excision Complete† 5 (7)    5 (7)    
 Incomplete 33 (29) 5.61 2.08-15.17 0.001 10 (9) 1.32 0.43-4.03 0.63 
Margin clearance >1mm 2 (7)    1 (4)    
 
 ≤1mm / not 
assessable 
36 (23) 3.84 0.87-16.94 0.08 14 (9) 2.63 0.33-20.80 0.36 
 
OR; Odds ratio, CI; Confidence interval 
* Binary logistic regression analysis 
†Complete excision is defined as a pathologically assessable margin that is free of tumour 
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To investigate which variables were most relevant to surgical decision-making, we analysed their 
impact on the risk of adverse events. On multivariate logistic regression analysis, the factors 
independently associated with an increased risk of adverse events were pathological evidence of 
incomplete excision (OR 10.23, 95% CI 4.24-24.64, p<0.001) and the presence of 
lymphovascular invasion (OR 2.65, 95% CI 1.14-6.15, p=0.023) (Table 4).  
 
 
Table 4. Multivariate analysis of risk factors associated with adverse events in all patients with 
screen-detected polyp cancers (binary logistic regression analysis). An adverse event is defined 
as (1) evidence of tumour in the resected specimen of patients undergoing segmental resection, 
(2) cancer-related death in any patient, (3) local or systemic disease recurrence in any patient.  
 
 
 
 
 
 
 
Risk factor  
Adverse events 
N (%) O.R. 95% CI p value* 
Age > 70 years 15 (11) 0.98 0.93 – 1.05 0.65 
Sex Male 43 (13) 1.06 0.45 – 2.47 0.90 
Charlson Comorbidity Index ≥3 (unfit) 26 (14) 1.61 0.72 – 3.62 0.25 
Polyp location Rectum 12 (14) 0.60 0.22 – 1.65 0.32 
Polyp size ≥ 10mm 44 (14) 1.72 0.62 – 4.71 0.30 
Polyp morphology Sessile 24 (16) 1.19 0.53 – 2.67 0.67 
Polyp differentiation Poor 6 (13) 1.78 0.49 – 6.43 0.38 
Lymphovascular invasion Present 16 (19) 2.65 1.14 – 6.15 0.023 
Completeness of excision Incomplete† 46 (24) 10.23 4.24 – 24.64 <0.001 
 
OR; Odds ratio, CI; Confidence interval 
*Multivariate binary logistic regression analysis 
†Defined as  pathological evidence of tumour extending to the diathermy edge or a margin that is not assessable 
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Using this data, we developed a treatment algorithm for patients with colorectal polyp cancers 
(Figure 3). This advocates that patients with completely excised polyp cancers without evidence 
of lymphovascular invasion are in a ‘low risk’ category (5% risk of adverse events) and can be 
followed up accordingly. Patients with completely excised polyp cancers but evidence of 
lymphovascular invasion are in a ‘medium risk’ category and should be considered for segmental 
resection (10% risk of adverse events). Finally, patients with incompletely excised polyp cancers 
are in a ‘high risk’ category and should be considered for segmental resection on the basis of a 
24% risk of adverse events (Figure 3). 
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DISCUSSION 
 
To our knowledge, the present study is the largest to have examined the treatment strategies and 
outcomes of patients with colorectal polyp cancers. By including every case identified since 
national screening began in Scotland over 15 years ago, we have been able to accurately define 
the incidence of screen-detected polyp cancers and provide an overview of current practice. 
 
As screening programmes detect increasing numbers of polyp cancers, it is crucial that their 
management is based on good quality evidence. With this in mind, we sought to answer several 
key questions related to treatment decisions. The first was whether patients diagnosed with a 
focus of malignancy within an excised polyp should be offered segmental resection or 
endoscopic surveillance. When making this decision, the patient and clinician must balance the 
morbidity of surgery against the risk of residual disease if a surveillance strategy is followed. In 
our series, 78% of the segmental resections demonstrated no evidence of residual tumour and 
could, in retrospect, be considered to have been unnecessary. Our figures are similar to those 
reported by Gill and co-workers from a study of malignant colorectal polyps in the North of 
England. In the 71 patients who underwent surgery, there was no evidence of residual tumour in 
82% 6. However, despite this apparent over-treatment, it must be remembered that a small 
number of patients did have residual tumour, including metastases to the regional lymph nodes in 
8%. An ideal predictive model would therefore identify those patients most likely to benefit from 
resection while preventing an excess of unnecessary operations. Previous studies have reported 
an array of ‘high risk’ pathological features, including polyp size19, location20, lymphovascular 
invasion 12, poor differentiation21, tumour budding 22, close or involved margins 12 22, sessile 
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morphology 23 and depth of submucosal invasion. The latter, in particular, is widely regarded as 
an important determinant of the likelihood of lymph node metastases and can be assessed in a 
number of different ways. One option is to use the ordinal grading systems such as those 
described by Kikuchi 16 and Haggitt 15. It should be emphasized, however, that these systems 
cannot be applied if the polypectomy specimen is too superficial to contain any muscularis 
propria; as should be the case after safe endoscopic excision of colonic or extraperitoneal rectal 
polyps. An alternative option is to employ a quantitative measurement of the breadth and depth 
of submucosal invasion in micrometres (μm). Using this technique, Ueno and colleagues 22 were 
able to predict which patients with early invasive cancers were likely to have lymph node 
metastases. While this method may have merit, such measurements are yet to be incorporated 
into standard pathological reporting of colorectal polyps in the United Kingdom and thus cannot 
yet play a role in polyp cancer decision-making. 
 
In fact, our data suggest that histopathological confirmation of complete excision is enough to 
confidently predict a low likelihood of residual disease in the bowel lumen. We found that 
patients with completely excised polyp cancers had a <10% risk of residual disease compared to 
>30% in those where the margin was either involved or not assessable. Interestingly, extending 
the margin clearance to at least 1mm, as suggested by several international guidelines, did not 
improve risk stratification. Similar results were observed in the Northern Colorectal Cancer 
Audit Group Study (NORCCAG) where the authors reported that any clear margin was adequate, 
even as small as 0.1mm 6. The caveat to these observations is that a small number of patients 
with completely excised lesions will have occult lymph node metastases at the time of their 
polypectomy. Clearly such patients would be best served by segmental resection but identifying 
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them is difficult. The only predictor of lymph node involvement in our series was the presence of 
lymphovascular invasion in the resected polyp. This is in line with findings from a pooled 
analysis of thirty one smaller studies, where the authors reported vascular invasion as the only 
factor associated with a higher rate of lymph node metastases 12. Although the association 
between lymphovascular invasion and nodal metastases is intuitive, it is worthy of attention for 
several reasons. First, lymphovascular invasion appeared to be an important risk factor in 
patients managed both operatively and conservatively. Given that there is evidence that the use 
of ‘elastica’ staining can increase the detection of venous invasion in colorectal cancers 24, the 
question must now be asked whether adopting such a policy would translate into improved risk 
stratification.  
  
The present study sought to report the long term outcomes of patients with polyp cancers and the 
most striking result was how few patients succumbed to their disease. Regardless of the type of 
treatment received, only 6% of patients developed tumour recurrence and less than 2% died of 
their disease. Decisions about how intensively to follow-up polyp cancers are for individual 
health authorities but our data suggests that endoscopic surveillance has a low diagnostic yield. 
One option, therefore, would be to simply apply existing British Society of Gastroenterology 
(BSG) adenoma surveillance guidelines 25.  
 
In addition to the treatment algorithm we have proposed, this study has highlighted a number of 
simple points of practice that have the potential to improve polyp cancer management. Treatment 
decisions are reliant on the quality of the initial endoscopy and subsequent pathological 
examination and having an intact specimen with an invasive margin that can be accurately 
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assessed is key. The endoscopist should make every effort to achieve this and to this end we 
would support the wider use of advanced endoscopic techniques such as Endoscopic Mucosal 
Resection (EMR)26 27. In addition, although a cancer diagnosis may not be unexpected, we would 
encourage a policy of tattooing all suspicious polyps; without which attempts at endoscopic 
surveillance or re-excision are difficult 28.  Finally, we would advocate a policy of didactic 
reporting for all colorectal polyp cancers.  
  
The main limitation to the present study was its retrospective nature. Treatment decisions had 
already been taken and the reasons behind them could often only be surmised.  However, the 
data was derived from every health board in the country and we believe it to be a true 
representation of current practice. Our results are also limited by the fact that information on 
certain pathological risk factors was not available. However, we would emphasize that this study 
was conducted primarily to develop a clinically useful treatment algorithm and with this in mind, 
we only included variables that were and are described on contemporary pathology reports. In 
the future we plan to conduct a central pathological review of all available polyp cancer 
specimens. This will give opportunity to examine additional risk factors, such a quantitative 
measurements of submucosal invasion22, tumour budding22, mismatch repair status29 and 
peritumoural inflammatory cell response30 that may be of equal or greater value in predicting 
outcomes.  Finally, our study was confined to polyps detected through population screening and 
it may be that the tumour biology of symptomatic lesions is different31. To address this, we are in 
the process of developing a national database of both incidental and screen-detected polyp 
cancers.  
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In conclusion, we have provided a treatment algorithm for patients with screen-detected 
colorectal polyp cancers. A policy of surveillance appears to be adequate for the majority of 
patients and consideration of segmental resection should be reserved for those with incomplete 
excision or evidence of lymphovascular invasion. To reduce uncertainty with these decisions, 
every effort should be made to obtain a single, intact resection specimen at the time of 
polypectomy. 
 
 
Figure Legends 
Figure 1. Summary data from the Scottish Bowel Screening Programme (SBoSP) showing the 
number of invitations sent, screening colonoscopies carried out and the number of non-polyp and 
polyp cancers diagnosed. The steep increase in 2007 reflects the end of the pilot programme and 
the start of the phased national rollout. 
 
Figure 2. Management strategies and outcomes of screen-detected polyp cancers in Scotland. An 
adverse event is defined as (1) residual tumour in the specimen following segmental resection, 
(2) cancer death or (3) local or systemic disease recurrence.  
 
Figure 3. The SSPoCS system: a proposed treatment algorithm for the management of patients 
with colorectal polyp cancers. The assessments of risk are based on the chance of adverse events, 
regardless of the management strategy chosen. 
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